CACI vs GEN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CACI exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust operational efficiency. While the current price of $516.54 is significantly above the defensive Graham Number ($313.75), it trades at a substantial discount to its growth-based intrinsic value of $688.83 and analyst targets. Despite bearish short-term technicals and insider selling, the company's consistent track record of earnings beats and double-digit EPS growth support a long-term bullish outlook.
GEN presents a stark contrast between strong growth fundamentals and deteriorating financial health and market sentiment. While the Piotroski F-Score of 4/9 indicates a stable but mediocre health profile, the current ratio of 0.47 and high debt-to-equity ratio of 3.63 signal significant short-term liquidity risks. Valuation is highly attractive on a forward basis (Forward P/E 6.40, PEG 0.47), but this is heavily offset by a bearish technical trend (0/100) and insider selling. The stock is currently trading near its 52-week low, suggesting the market is pricing in balance sheet fragility over growth potential.
Compare Another Pair
Related Comparisons
CACI vs GEN: Head-to-Head Comparison
This page compares CACI International Inc (CACI) and Gen Digital Inc. (GEN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.